Study of immune-suppressed people in Cologne
Part of Blood & lymphatic, Cancer clinical trials.
This study follows people whose immune systems are weakened (immunosuppressed). Researchers want to better understand what happens in this group, and what risks or outcomes may occur.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently immunosuppressed (your immune system is weakened).
- You can participate in a patient follow-up study as requested by the study team.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how changing your immune system (with earlier treatments) affects cancer by collecting immune cells from your blood using a process called lymphapheresis. It may help researchers find better ways to monitor immune-related responses and side effects.
This is an observational study that follows adults with solid cancer who are receiving immune checkpoint inhibitor treatments. It aims to learn how these medicines are used and what outcomes may look like in everyday care.
This study looks at people with certain types of blood cancer (lymphoma or leukemia) who are getting immunotherapy drugs called checkpoint inhibitors. Researchers want to learn how these drugs affect the body's hormone system, so doctors can better manage these side effects.
This study looks at how your immune system “rebuilds” after certain cell-based cancer treatments or stem cell transplants. It may help researchers better understand why immune recovery differs between people and how to improve protection against infections.
This study aims to understand the immune system in people who have immune problems or whose immune-related diseases are not helped by standard treatments. It may lead to better ways to diagnose and treat these conditions.
This study looks at how well antiviral treatments work in people with weakened immune systems who get COVID-19. It focuses on patients treated with two specific antivirals and aims to understand their outcomes.
Hear when a new Hematological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.